CTOs on the Move

Surface Ophthalmics

www.surfaceophthalmics.com

 
Surface Ophthalmics, Inc. is a pharmaceutical company focused on development and commercialization of innovative therapeutics for ocular diseases.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Surface Ophthalmics raised $25M on 06/10/2021

Similar Companies

Nostrum Laboratories

Nostrum Laboratories is a Kansas City, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BCY LifeSciences

BCY LifeSciences Inc. is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PillPack

Pharmacy Simplified. We leverage service and technology to simplify the management of complex medication regimes for the 32 million people taking more than 5 medications a month. PillPack uses design to create an unparalleled patient experience that is both satisfying and effective.

Ridgmar Pharmacy

Ridgmar Pharmacy is a Fort Worth, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ORIC Pharmaceuticals

ORIC was established in 2014 with a bold vision of Overcoming Resistance in Cancer. Resistance limits the efficacy of otherwise significant cancer treatment breakthroughs, regardless of modality. Our ambition at ORIC is to discover and develop innovative therapies that benefit patients with cancer, including by making existing therapies more effective for a longer period of time. Our initial project was a small molecule antagonist of the glucocorticoid receptor (GR), which has been implicated in resistance to various treatment modalities—including chemotherapy, immunotherapy, and anti-hormonal therapy—and across multiple cancers. The resulting product candidate, ORIC-101, is now being studied in clinical trials for a range of solid tumors. ORIC-101 and other pipeline programs are a result of rigorous, hands-on experimentation and medicinal chemistry efforts led by our internal team of scientists in biology, medicinal chemistry, DMPK and translational medicine, with assistance from academic collaborators and continued guidance from our founders and board members. This collective team maintains an unwavering focus on improving the lives of patients by tackling the problem of cancer treatment resistance.